Клинические рекомендации по диагностике и лечению атипичного гемолитико-уремического синдрома. Разработчик: Научное общество нефрологов России. Утверждены Президиумом правления Научного общества нефрологов России 18 декабря 2014 г.
Abstract
Разработчик: Научное общество нефрологов России Рабочая группа: Профессор Козловская Н.Л. Профессор Прокопенко Е.И. Доцент Эмирова Х.М. К.м.н. Серикова С.Ю. Утверждены Президиумом правления Научного общества нефрологов России 18 декабря 2014 г. г. Москва 2014 г.
References
1. Ariceta G., Besbas N., Johnson S. et al. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 2009; 24: 687-696.
2. Barbour T., Johnson S., Cohney S. et al. Thrombotic microangiopathy and associated renal disorders. Nephrol Dial Transplant 2012; 27: 2673-2685.
3. Campistol J.M., Arias M., Ariceta G et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nephrologia 2013; 33(1): 27-45.
4. Cataland SR, Haifeng M.Wu. Atypical haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura: clinically differentiating the thrombotic microangiopatheis. Eur J Intern Med. 2013;24:486-491.
5. Fakhouri F, Delmas Y, Provot F. et al. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases. AJKD 2013; http://dx.doi.org/10.1053/ j.ajkd.2013.07.011
6. Kavanagh D., Goodship T.H.J. Atypical hemolytic uremic syndrome. Curr Opin Hematol 2010; 17(5):432-438.
7. Laurence J. Atypical haemolytic uraemic syndrome (aHUS): treating the patient. Clin Adv Hematol Oncol 2013; 11(10), Suppl.15:3-15
8. Legendre CM, Licht C, Greenbaum LA et al. Terminal complement inhibitor eculizumab in atypical haemolytic uraemic syndrome. N Engl J Med. 2013; 368(23):2169-2181.
9. Loirat C, Garnier A, Sellier-Leclerc AL, Kwon T. Plasmatherapy in atypical haemolytic uraemic syndrome. Semin Thromb Hemost 2010:36:673-681
10. Лора Ш., Фремю-Бачи В. Атипичный гемолитико- уремический синдром// Нефрология.- 2012; т. 16, №2, с.16-48.
11. Meri S. Complement activation in deseases presenting with thrombotic microangiopathy. Eur J Intern Med. 2013; http://dx.doi.org/10.1016/ j.ejim.2013.05.009
12. Nester C.M., Thomas C.P. Atypical hemolytic uremic syndrome: what is this, how is it diagnosed, and how is it treated? Hematology Am Soc Hematol Educ Program. 2012:617-25.
13. Noris M., Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 1676-87.
14. Noris M., Caprioli J, Bresin E. et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010; 5:1844-1859
15. Scully M., Hunt B.J., Bemjamin S. et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopatheis. BJH 2012; 158 (3): 323-335.
16. Scully M., Goodship T. How I treat thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome. BJH 2014; doi:10.1111/bjh.12718
17. Taylor CM, Machin S, Wigmore SJ, Goodship THJ. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. BJH.2009;148:37-47
18. Tsai HM. Thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome. An Update. Hematol Oncol Clin N Am 2013;27:565-584
19. Zuber J., Fakhouri F., Roumenina L.T. et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopahties. Nat. Rev. Nephrol. 2012; 8, 643-657.
20. Zuber J., Le Quintrec M, Sberro-Soussan R. Et al. New Insight into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol. 2011;7:23-35
Review
For citations:
. Nephrology and Dialysis. 2015;17(3):242-264. (In Russ.)
Views:
41
Email this article 